Latest Pharma and Biotech News
Pharmaceutical
21 November 2024 Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care.
Today's issue
Refine Search
Biotechnology
Finland-based Faron Pharmaceuticals, a biopharma reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, has announced that its chief executive Markku Jalkanen is to retire. 7 August 2024
Biotechnology
Shares of US therapeutic gene editing company Sangamo Therapeutics leapt as much as 46% to $1.11 yesterday on the news of a licensing deal. 7 August 2024
Biotechnology
Tuesday was a good day for Levicept, a UK biotech focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis and other pain indications. 7 August 2024
Biotechnology
US biotech major Amgen reported second quarter 2024 financial results late yesterday, showing total revenues increased 20% to $8.4 billion in comparison to the like quarter of 2023. 7 August 2024
Biotechnology
US clinical-stage biotech Equillium saw its shares rise 8% to $0.68 as it revealed progress with its first-in-class anti-CD6 monoclonal antibody. 6 August 2024
Biotechnology
Daiichi Sankyo (and US pharma giant Merck & Co have expanded their existing global co-development and co-commercialization agreement to include Merck’s MK-6070. 6 August 2024
Biotechnology
The US subsidiary of Swiss family-owned protein specialist Octapharma today revealed that the US Food and Drug Administration (FDA) has expanded the approval of fibryga, fibrinogen (human) lyophilized powder for reconstitution, for fibrinogen replacement in bleeding patients with acquired fibrinogen deficiency (AFD). 6 August 2024
Biotechnology
Shares of Swiss antibody drug conjugates (ADCs) develop ADC Therapeutics were down more than 11% at $2.55 as it reported financial results for 2nd-qtr 2024 and provided operational updates. 6 August 2024
Biotechnology
Actinium Pharmaceuticals’ shares closed down 60% yesterday and fell a further 10% to $2.23 in after-hours trading, when the company announced a regulatory setback for its Iead candidate. 6 August 2024
Biotechnology
US clinical-stage MBX Biosciences yesterday announced a $63.5 million Series C financing led by Deep Track Capital, 6 August 2024
Biotechnology
California’s BioMarin Pharmaceutical (Nasdaq: BMRN) has announced a strategic pivot for its Roctavian (valoctocogene roxaparvovec-rvox) business, focusing on the USA, Germany, and Italy. 6 August 2024
Biotechnology
In Singapore, a division of Kyowa Kirin (TSE:4151), has announced plans to sell the firm’s Chinese business while reducing focus on small molecules, as part of a regional overhaul. 6 August 2024
Biotechnology
Biotech incubators Two River and Third Rock Ventures have launched TRC 2004, a new company focusing on bispecific T-cell engagers (BiTE), according to a filing with the Hong Kong Stock Exchange. 6 August 2024
Biotechnology
Agenus has revealed via a Securities and Exchange Commission (SEC) filing that US pharma major Bristol Myers Squibb (NYSE: BMS) was pulling out of a licensing deal. 5 August 2024
Biotechnology
US immune-oncology firm iTeos Therapeutics today announced the appointment of David Feltquate as chief medical officer (CMO). 5 August 2024
Biotechnology
German biotech BioNTech today reported financial results for the three ended June 30, 2024, which failed to impress.. 5 August 2024
Biotechnology
Californian firm Anivive Lifesciences is broadening its scope from animal health to human vaccines with a significant new funding grant. 5 August 2024
Biotechnology
Shares of Genmab dipped 2.6% to 1,867 kroner in early trading, as the Danish drugmaker revealed that the return of rights to acasunlimab by German biotech BioNTech 5 August 2024
Biotechnology
Brussels-based UCB (OTCMKTS: UCBJF) has announced that it has received marketing authorization from the European Commission for two new 320 mg device presentations of Bimzelx (bimekizumab). 5 August 2024
Biotechnology
Jade Biosciences (Nasdaq: JAD), a biotechnology company specializing in the development of therapies for autoimmune diseases, has announced the successful closing of an $80 million financing round. 5 August 2024
All news
Biotechnology
California-based venture capital firm Versant Ventures yesterday announced the launch of Pep2Tango Therapeutics, a start-up focused on innovative, next-generation weight loss therapies. Proceeds from the significant, undisclosed round will support development of the company’s novel unimolecular tetra-receptor agonist peptides to treat obesity and related conditions. 22 November 2024
Biotechnology
Hong Kong-based Sino Biopharm has signed an equity investment and strategic collaboration agreement with LaNova Medicines, advancing its oncology focus. 22 November 2024
Biotechnology
British pharma major AstraZeneca is facing challenges in its bid to secure full approval for its anticoagulant reversal therapy, Andexxa (andexanet alfa), in the USA. 22 November 2024
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Biotechnology
San Diego-based Cidara Therapeutics, a biotech using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, has entered into a securities purchase agreement with certain investors to raise up to around $105 million. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
Eli Lilly is not resting on its laurels when it comes to the fast-growing field of obesity treatments, an area in which it is already a leader. 21 November 2024
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
San Diego-based Valora Therapeutics, a biotech that boasts of having a novel approach to immunotherapy, has announced the successful closing of a $30 million seed funding round. 21 November 2024
Biotechnology
Astellas Pharma has been hit by bad news from the US Food and Drug Administration, which will not currently approve the firm’s request to supplement the label for Izervay (avacincaptad pegol). 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Biotechnology
HCW Biologics has announced a worldwide licensing agreement with WY Biotech to develop and commercialize one of its preclinical immunotherapy candidates. 21 November 2024
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
US clinical-stage biotech Vyriad has entered into a strategic collaboration with Swiss pharma giant Novartis to discover and develop in vivo chimeric antigen receptor (CAR) T-cell therapies. 21 November 2024
Biotechnology
The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer. 20 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze